Dishman Carbogen Amcis Ltd
NSE:DCAL
Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
Dishman Carbogen Amcis Ltd. is a manufacturing company, which engages in the provision of outsourcing services for the pharmaceutical industry. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2017-09-21. The firm's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The firm assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The firm has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The firm's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.
Revenue Growth: Quarterly revenue rose 5.5% year-over-year to INR 720 crores, though some shipments were delayed and will be recognized in Q4.
Profitability: The company reported a quarterly loss after tax of INR 12.97 crores, mainly due to higher costs, severance expenses, and a one-time finance charge.
EBITDA Margin: For the first 9 months, EBITDA margin improved to 19.4% from 15.9% last year, with full-year margin guidance of 19.5–20% reaffirmed.
CDMO Segment: CDMO revenue grew, especially from development projects, with a trend expected to continue next year.
Bavla Site Guidance: Revenue from the Bavla site is on track to reach around INR 250 crores for FY '26, with stronger growth anticipated in FY '27.
Pipeline & Orders: The company has issued INR 1,200 crores worth of RFPs from India, expecting a 30–35% conversion rate, aiming for INR 500 crores revenue from India within 12–18 months.
Capacity Utilization: Utilization levels vary by site, with India and France at around 20–25%. No capacity constraints are currently seen.
ADC Business: Significant ramp-up expected from ADC molecules, with ongoing co-investments to meet client demand. Estimated revenue from a major ADC customer to grow from CHF 22 million last year to CHF 40 million next year and increase further with new investments.
French Subsidiary: The French facility is expected to break even next year, with projected FY '27 revenue around EUR 18 million.
Debt Plan: Net debt stands at CHF 150 million; the company plans to pay off INR 750 crores of India debt within three years from internal accruals.
